AI Article Synopsis
- A trial, STOPDAPT-3, was conducted to compare aspirin monotherapy and clopidogrel monotherapy after short-term dual antiplatelet therapy in patients who underwent percutaneous coronary intervention using drug-eluting stents.
- The study involved 5,833 patients who were followed for 30 days, focusing on cardiovascular events (like heart attacks) and bleeding complications as primary endpoints.
- Results showed that aspirin and clopidogrel monotherapy had similar rates of cardiovascular and bleeding events up to one year after the intervention, indicating both treatments are equally effective in these contexts.
Article Abstract
Background And Aims: There was no previous trial comparing aspirin monotherapy with a P2Y12 inhibitor monotherapy following short dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stents.
Methods: In the STOPDAPT-3, patients with acute coronary syndrome or high bleeding risk (HBR) were randomly assigned to either 1-month dual antiplatelet therapy with aspirin and prasugrel followed by aspirin monotherapy (aspirin group) or 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). This secondary analysis compared aspirin monotherapy with clopidogrel monotherapy by the 30-day landmark analysis. The co-primary endpoints were the cardiovascular endpoint defined as a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischaemic stroke and the bleeding endpoint defined as Bleeding Academic Research Consortium 3 or 5.
Results: Of the 6002 assigned patients, 5833 patients (aspirin group: N = 2920 and clopidogrel group: N = 2913) were included in the 30-day landmark analysis. Median age was 73 (interquartile range 64-80) years, women 23.4%, acute coronary syndrome 74.6%, and high bleeding risk 54.1%. The assigned monotherapy was continued at 1 year in 87.5% and 87.2% in the aspirin and clopidogrel groups, respectively. The incidence rates beyond 30 days and up to 1 year were similar between the aspirin and clopidogrel groups for both cardiovascular endpoint [4.5 and 4.5 per 100 person-year, hazard ratio 1.00 (95% confidence interval .77-1.30), P = .97], and bleeding endpoint [2.0 and 1.9, hazard ratio 1.02 (95% confidence interval .69-1.52), P = .92].
Conclusions: Aspirin monotherapy compared with clopidogrel monotherapy was associated with similar cardiovascular and bleeding outcomes beyond 1 month and up to 1 year after percutaneous coronary intervention with drug-eluting stents (STOPDAPT-3 ClinicalTrials.gov number, NCT04609111).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehae617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-World Analyses of the De-Escalation of Dual Antiplatelet Therapy in Treatment of Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention in Taiwan.
Acta Cardiol Sin
January 2025
Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University.
Background: Dual antiplatelet therapy (DAPT) is the standard treatment for acute myocardial infarction (MI). This study aimed to investigate the use of DAPT and de-escalation after discharge in real-world practice among patients with acute MI undergoing percutaneous coronary intervention (PCI) in Taiwan.
Methods: Using the Taiwan National Health Insurance Research Database, we included patients who received PCI for acute MI and survived to discharge with DAPT from 2011 to 2021.
Transient Ischaemic Attack in a Patient With Conn Syndrome: A Case Report and Literature Review on the Importance of Identifying Secondary Hypertension.
In Vivo
December 2024
Department of Health and Care Professions, Faculty of Health and Life Sciences, University of Exeter, Exeter, U.K.;
Background/aim: Transient ischaemic attack (TIA) is characterised by a temporary neurological dysfunction resulting from focal ischaemia in the brain, spinal cord or retina without acute infarction. These episodes typically last less than 24 hours and are significant predictors of subsequent ischaemic strokes. Hypertension is a major risk factor for cerebrovascular events, and primary aldosteronism (PA) is recognised as a common cause of secondary hypertension.
View Article and Find Full Text PDFOptimal Long-term Antiplatelet Regimen for Patients with High Ischaemic and Bleeding Risks After Percutaneous Coronary Intervention.
Thromb Haemost
December 2024
Internal Medicine, Cardiovascular Centre, Department of Internal Medicine, Gyeongsang National University School of Medicine, Gyeongsang National University Changwon Hospital, Changwon-si, Korea (the Republic of).
Aim To assess an optimal long-term antiplatelet strategy in patients at both high ischaemic and bleeding risks after percutaneous coronary intervention (PCI). Methods and results Patients both at high ischaemic and bleeding risks were eligible for inclusion. We excluded patients with any ischaemic and major bleeding complications during the mandatory period of dual antiplatelet therapy (DAPT).
View Article and Find Full Text PDFProlonged antithrombotic treatment after de-escalation of dual antiplatelet therapy in patients after acute coronary syndrome - which strategy should be applied? The ELECTRA-SIRIO 2 investigators standpoint.
Int J Cardiol
December 2024
Department of Clinical and Interventional Cardiology, Sassari University Hospital, Sassari, Italy.
De-escalation of dual antiplatelet (DAPT) intensity may be considered in patients with high risk of bleeding after acute coronary syndrome. Some high risk patients after de-escalation may require antithrombotic therapy prolonged over 12 months. With the current guideline recommended strategies, there are some doubts and uncertainties with respect to the transition period.
View Article and Find Full Text PDFThe chemoprotective effect of anti-platelet agents on cancer incidence in people with non-alcoholic fatty liver disease (NAFLD): a retrospective cohort study.
BMC Med
December 2024
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
Article Synopsis
- Non-alcoholic fatty liver disease (NAFLD) is linked to higher rates of liver and obesity-related cancers, prompting researchers to investigate the protective effects of aspirin and other anti-platelet drugs on these cancers.
- A study analyzed medical records of adults with NAFLD to compare the cancer incidence between those taking antiplatelet medication for at least a year versus those who weren't, following them for five years.
- Results indicated that antiplatelet use significantly lowered the risk of obesity-related cancers, including hepatocellular carcinoma (HCC), breast, pancreatic, and colorectal cancers, with aspirin alone showing a major decrease in HCC incidence.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!